Gloheal

Mumbai, India Founded: 2015 • Age: 11 yrs Listed
Provides a virtual consultation platform for users.
Request Access
Report Incorrect Data
Page last updated

About Gloheal

Gloheal is a publicly listed company based in Mumbai (India) founded in 2015. It provides a virtual consultation platform for users. It operates on a B2C model. The company has 5,895 employees. Its Indian entity Tata Communications Limited reported revenue of ₹25,104 Cr. Its focus areas include Healthcare and Services, Telehealth, Consultation Platforms and Virtual Services. Its competitors include Amwell, Truepill, VSee, eVisit and Bright.md and 4 more; 9 of its 9 listed competitors have raised funding.

Company details

Gloheal provides a virtual consultation platform for users, focusing on healthcare and services, providing telehealth services, consultation platforms, and virtual services. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.

  • Headquarters Mumbai, India
  • Employees 5,895
  • Stage Public
  • Sectors
    Healthcare
  • Website gloheal.com
  • Legal Name Tata Communications Limited
  • Date of Incorporation 19 Mar, 1986
  • Jurisdiction Mumbai, Maharashtra, India
Operational Areas
Healthcare → Digital Health & Telemedicine
Key Metrics
  • Market Cap
    ₹48,992 Cr

    TATACOMM · NSE

  • Share Price
    ₹1,718.50

    -1.39% today

  • Revenue
    ₹24,803 Cr

    FY 2025-26 · +7.3% YoY

  • EBITDA
    ₹4,605 Cr

    Margin 18.6%

  • Net Profit
    ₹1,055 Cr

    FY 2025-26 · -20.8% YoY

  • P/E (TTM)
    41.0x

    P/B 14.6x

  • ROE
    28.5%

    ROCE 11.6%

  • Debt / Equity
    3.80

    Interest cover 42.8x

  • Employee Count
    5,895

Board of directors of Tata Communications Limited (Gloheal)

Tata Communications Limited is the primary company behind Gloheal. The board of Tata Communications Limited currently have 8 directors; the longest-serving is Krishnakumar Natarajan, appointed in 2021. 39 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Krishnakumar Natarajan
DIN 00147772
Director15 Jul 20215 yrs 3 moTata Communications Limited
Ashok Sinha
DIN 00070477
Director08 Oct 20215 yrsTata Communications Limited
Ganapathy Subramaniam Natarajan
DIN 07006215
Director02 Dec 20214 yrs 10 moTata Communications Limited
Ankur Verma
DIN 07972892
Director19 Apr 20233 yrs 6 moTata Communications Limited
Sangeeta Anand
DIN 10715306
Director05 Sep 20242 yrs 1 moTata Communications Limited
Sujit Kumar Varma
DIN 09075212
Director22 Apr 20251 yr 5 moTata Communications Limited
Pappu Jagdish Rao
DIN 01991594
Director13 Jun 20251 yr 4 moTata Communications Limited
Ganapathi Subramanian Lakshminarayanan
DIN 01828104
Additional Director20 May 20265 moTata Communications Limited

IPO & Listings of Gloheal

Gloheal is a publicly listed company on the NSE with ticker symbol TATACOMM in India, operating in the Telecom-Service sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: TATACOMM
  • Listed entityTata Communications Limited
  • Exchange sectorTelecom-Service

Financials of Gloheal

Exchange-reported figures of Tata Communications Limited, the listed company behind Gloheal (NSE: TATACOMM).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹24,803 Cr
+7.3% YoY
EBITDA
₹4,605 Cr
+6.1% YoY
Profit After Tax
₹1,055 Cr
-20.8% YoY
Net Worth
₹3,447 Cr
+14.1% YoY
Total Assets
₹19,079 Cr
+5.2% YoY
Total Debt
₹12,249 Cr
-0.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue24,80323,10920,96917,83816,72517,10017,068
Revenue growth+7.3%+10.2%+17.6%+6.7%-2.2%+0.2%-
EBITDA4,6054,3423,9924,3184,1914,0942,898
EBITDA margin+18.6%+18.8%+19.0%+24.2%+25.1%+23.9%+17.0%
Profit before tax1,3962,2811,1632,0632,0001,609140
Net profit1,0551,3311,0781,7311,4731,271(613)
Net profit margin+4.3%+5.8%+5.1%+9.7%+8.8%+7.4%-3.6%
EPS (₹)35.1464.4333.9863.0251.9943.88(3.02)
Balance sheet
Total assets19,07918,13816,39013,53013,38214,89314,982
Net worth3,4473,0211,7861,518928115(1,278)
Total debt12,24912,35711,2638,5779,12211,39412,413
Cash & bank6955878421,063743927909
Net working capital(2,641)(1,983)(2,126)(1,938)(1,819)(1,858)(1,868)
Cash flow
Cash from operations4,4792,9113,1824,3844,2043,1802,525
Cash from investing(1,434)(2,173)(2,641)(1,836)(894)(2,007)(1,521)
Cash from financing(2,937)(936)(813)(2,241)(3,431)(1,205)(942)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6,6886,5836,5546,1896,1005,9605,9905,798
Revenue growth (YoY)+9.6%+10.5%+9.4%+6.7%+6.5%+6.6%--
Other income16.4112.9462.84259(17.24)17.101,00828.73
EBITDA1,3851,1241,2841,1511,1531,0741,0401,145
EBITDA margin+20.7%+17.1%+19.6%+18.6%+18.9%+18.0%+17.4%+19.9%
Depreciation741739731751679666672637
Interest198186182201202177182187
Profit before tax4632114344582552491,193350
Tax12486.0118310182.1365.43176126
Net profit3391252513571731841,017224
EPS (₹)11.944.709.2212.806.416.6536.478.28
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue7,3767,2787,9927,2366,5876,2255,750
Revenue growth+1.3%-8.9%+10.4%+9.9%+5.8%+8.3%-
EBITDA1,7001,2351,7081,5231,9561,9431,224
EBITDA margin+23.1%+17.0%+21.4%+21.1%+29.7%+31.2%+21.3%
Profit before tax1,0141,2029409811,5201,229374
Net profit7686057358451,155926348
Net profit margin+10.4%+8.3%+9.2%+11.7%+17.5%+14.9%+6.1%
EPS (₹)27.8636.8722.4123.3740.9633.787.33
Balance sheet
Total assets17,28315,03113,95211,57911,45710,7809,920
Net worth10,57910,4519,8909,8619,8039,0678,221
Total debt5,4873,9023,1769629481,0321,012
Cash & bank250247321305101249164
Net working capital248(1,697)(1,730)(1,507)(258)(1,511)(1,446)
Cash flow
Cash from operations1,5041,5972,1062,0872,1731,6471,108
Cash from investing(1,935)(1,381)(3,500)(1,224)(1,708)(1,454)(1,093)
Cash from financing434(290)1,410(710)(563)(159)1.21
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,8541,8391,8811,8691,8031,8231,8601,815
Revenue growth (YoY)+2.9%+0.9%+1.1%+3.0%+0.5%+0.8%--
Other income73.4176.0010332314212576271.34
Total expenses1,3881,4131,3971,4591,3521,4661,5041,398
EBITDA466426484410451357357417
EBITDA margin+25.1%+23.2%+25.7%+21.9%+25.0%+19.6%+19.2%+23.0%
Depreciation276271270262264248245243
Interest94.3292.0088.1693.2389.7665.5768.1965.55
Profit before tax169139230377239168805180
Tax42.7434.4861.0899.1528.2431.7810847.82

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 20 Oct 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6,6886,5836,5546,1896,1005,9605,9905,798
Revenue growth (YoY)+9.6%+10.5%+9.4%+6.7%+6.5%+6.6%--
Other income16.4112.9462.84259(17.24)17.101,00828.73
EBITDA1,3851,1241,2841,1511,1531,0741,0401,145
EBITDA margin+20.7%+17.1%+19.6%+18.6%+18.9%+18.0%+17.4%+19.9%
Depreciation741739731751679666672637
Interest198186182201202177182187
Profit before tax4632114344582552491,193350
Tax12486.0118310182.1365.43176126
Net profit3391252513571731841,017224
EPS (₹)11.944.709.2212.806.416.6536.478.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue24,80323,10920,96917,83816,72517,10017,068
Revenue growth+7.3%+10.2%+17.6%+6.7%-2.2%+0.2%-
Other income3791,26028444037424869.68
Total expenses20,19818,76716,97613,52012,53413,00614,170
Employee cost4,9394,5574,4533,5973,0403,0493,039
EBITDA4,6054,3423,9924,3184,1914,0942,898
EBITDA margin+18.6%+18.8%+19.0%+24.2%+25.1%+23.9%+17.0%
Depreciation2,8272,5922,4702,2622,2052,3142,358
Interest762729644432360420471
Profit before tax1,3962,2811,1632,0632,0001,609140
Tax432486214297522355227
Net profit1,0551,3311,0781,7311,4731,271(613)
Net profit margin+4.3%+5.8%+5.1%+9.7%+8.8%+7.4%-3.6%
EPS (₹)35.1464.4333.9863.0251.9943.88(3.02)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital285285285285285285285
Reserves & surplus3,1622,7361,5011,233643(170)(1,563)
Shareholders' funds (net worth)3,4473,0211,7861,518928115(1,278)
Minority interest2043.113.8830.3428.4928.174.75
Secured loans0.000.000.001,0505255240.00
Unsecured loans12,24912,35711,2637,5278,59710,87012,413
Total debt12,24912,35711,2638,5779,12211,39412,413
Total liabilities19,07918,13816,39013,53013,38214,89314,982
Assets
Gross block44,22639,05538,98836,10135,51035,39535,439
Net block15,48113,91913,46710,50010,93611,52012,768
Capital work in progress8501,1001,3271,148852493349
Investments2,2972,7141,6081,9511,5652,2331,563
Inventories10015883.5416037.8834.4472.97
Sundry debtors4,1714,0063,7582,7352,5822,6083,229
Cash & bank balances6955878421,063743927909
Loans & advances1,6001,5721,1651,0941,0749851,069
Total current assets6,5676,3235,8505,0514,4374,5555,280
Total current liabilities9,2088,3067,9766,9896,2566,4127,149
Net working capital(2,641)(1,983)(2,126)(1,938)(1,819)(1,858)(1,868)
Total assets19,07918,13816,39013,53013,38214,89314,982
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash5347321,004697818850789
Net cash from operating activities4,4792,9113,1824,3844,2043,1802,525
Net cash from investing activities(1,434)(2,173)(2,641)(1,836)(894)(2,007)(1,521)
Net cash from financing activities(2,937)(936)(813)(2,241)(3,431)(1,205)(942)
Net change in cash108(198)(272)308(121)(32.15)60.94
Closing cash6955878421,063743927909
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+7.3%+10.2%+17.6%+6.7%-2.2%+0.2%-
EBITDA growth+6.1%+8.8%-7.5%+3.0%+2.4%+41.3%-
PBT growth-38.8%+96.1%-43.6%+3.2%+24.3%+1051.8%-59.3%
Net income growth-20.8%+23.6%-37.7%+17.5%+15.9%+307.3%-
Revenue CAGR (3Y)+11.6%+11.4%+7.0%+1.5%+0.4%+0.7%-1.1%
EBITDA CAGR (3Y)+2.2%+1.2%-0.8%+14.2%+15.2%+26.2%+29.2%
Profitability & leverage
Net income margin+3.9%+7.8%+4.5%+9.9%+8.8%+7.3%-0.5%
Return on capital employed+11.6%+11.5%+12.1%+15.6%+13.3%+12.0%0.0%
Return on net worth+28.5%+38.2%+30.6%+46.7%+35.5%+84.9%0.0%
Debt / equity3.804.916.007.2419.670.000.00
Long-term debt / equity2.563.124.225.7816.360.000.00
Interest cover42.8341.6642.3021.0318.1423.6087.06
Efficiency & per share
Fixed asset turnover0.600.590.560.500.470.480.51
Inventory turnover192.12191.47172.20180.29462.52318.41228.26
Debtors turnover6.075.956.466.716.455.865.51
EPS (₹)35.1464.4333.9863.0251.9943.88(3.02)
Dividend per share (₹)17.5025.0016.7021.0020.7014.004.00
Book value per share (₹)120.95106.0162.6853.2732.554.05(44.85)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,8541,8391,8811,8691,8031,8231,8601,815
Revenue growth (YoY)+2.9%+0.9%+1.1%+3.0%+0.5%+0.8%--
Other income73.4176.0010332314212576271.34
Total expenses1,3881,4131,3971,4591,3521,4661,5041,398
EBITDA466426484410451357357417
EBITDA margin+25.1%+23.2%+25.7%+21.9%+25.0%+19.6%+19.2%+23.0%
Depreciation276271270262264248245243
Interest94.3292.0088.1693.2389.7665.5768.1965.55
Profit before tax169139230377239168805180
Tax42.7434.4861.0899.1528.2431.7810847.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue7,3767,2787,9927,2366,5876,2255,750
Revenue growth+1.3%-8.9%+10.4%+9.9%+5.8%+8.3%-
Other income6951,187426544569366182
Total expenses5,6766,0436,2845,7134,6324,2834,526
Employee cost1,6271,5391,7431,5531,2791,105999
EBITDA1,7001,2351,7081,5231,9561,9431,224
EBITDA margin+23.1%+17.0%+21.4%+21.1%+29.7%+31.2%+21.3%
Depreciation1,0449841,038996916973977
Interest33723615690.0488.5910755.19
Profit before tax1,0141,2029409811,5201,229374
Tax220151301315353267165
Net profit7686057358451,155926348
Net profit margin+10.4%+8.3%+9.2%+11.7%+17.5%+14.9%+6.1%
EPS (₹)27.8636.8722.4123.3740.9633.787.33
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital285285285285285285285
Reserves & surplus10,29410,1669,6059,5769,5188,7827,936
Shareholders' funds (net worth)10,57910,4519,8909,8619,8039,0678,221
Secured loans0.000.000.005255255272.79
Unsecured loans5,4873,9023,1764374235051,009
Total debt5,4873,9023,1769629481,0321,012
Total liabilities17,28315,03113,95211,57911,45710,7809,920
Assets
Gross block15,73715,02715,34515,30216,27715,51114,907
Net block5,7405,2295,3345,0055,0605,0615,252
Capital work in progress445648731701448205149
Investments7,7747,0956,0834,4174,2774,7364,038
Inventories7.2646.8833.4211517.7718.0568.32
Sundry debtors1,3671,1881,2281,1621,1041,0901,300
Cash & bank balances250247321305101249164
Loans & advances2,6746725205971,783550592
Total current assets4,2992,1542,1022,1793,0051,9072,123
Total current liabilities4,0513,8513,8323,6863,2633,4183,569
Net working capital248(1,697)(1,730)(1,507)(258)(1,511)(1,446)
Total assets17,28315,03113,95211,57911,45710,7809,920
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19426825298.78198163146
Net cash from operating activities1,5041,5972,1062,0872,1731,6471,108
Net cash from investing activities(1,935)(1,381)(3,500)(1,224)(1,708)(1,454)(1,093)
Net cash from financing activities434(290)1,410(710)(563)(159)1.21
Net change in cash3.10(73.87)15.56153(98.72)34.5516.71
Closing cash250247321305101249164
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.3%-8.9%+10.4%+9.9%+5.8%+8.3%-
EBITDA growth+37.7%-27.7%+12.1%-22.1%+0.7%+58.7%-
PBT growth-15.6%+27.9%-4.2%-35.5%+23.7%+229.1%+9998.0%
Net income growth+26.8%-17.7%-13.1%-26.8%+24.8%+166.1%-
Revenue CAGR (3Y)+0.6%+3.4%+8.7%+8.0%+6.9%+5.8%+4.3%
EBITDA CAGR (3Y)+3.7%-14.2%-4.2%+7.6%+51.8%+23.3%+56.3%
Profitability & leverage
Net income margin+10.8%+14.4%+8.0%+9.2%+17.7%+15.5%+3.6%
Return on capital employed+8.4%+6.0%+10.0%+11.7%+14.5%+12.9%+8.0%
Return on net worth+7.6%+5.9%+7.4%+8.6%+12.4%+11.1%+4.2%
Debt / equity0.450.350.210.100.100.120.09
Long-term debt / equity0.190.220.130.060.100.080.04
Interest cover51.3493.9623.2417.088.5211.0022.34
Efficiency & per share
Fixed asset turnover0.480.480.520.460.410.410.41
Inventory turnover272.47181.27107.44108.73367.80144.1587.51
Debtors turnover5.776.026.696.396.015.214.43
EPS (₹)27.8636.8722.4123.3740.9633.787.33
Dividend per share (₹)17.5025.0016.7021.0020.7014.004.00
Book value per share (₹)371.18366.71347.02346.01343.95318.12288.44

Competitors of Gloheal

Gloheal has 9 listed competitors in our database, 9 of them funded. They include Amwell, Truepill, VSee, eVisit and Bright.md, among others.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Amwell
amwell.com2006Boston, United States$887.35M742
Telehealth solutions are provided for doctors and patients' consultations.
Truepill
truepill.com2016Hayward, United States$322.12M–
Medicines are ordered and delivered through an API-connected healthcare app.
VSee
vsee.com2008Sunnyvale, United States$3.02M8
Secure video platforms for telehealth, education, and enterprises are provided.
eVisit
evisit.com2013Gilbert, United States$71.71M53
A virtual care platform is provided for health systems by eVisit.
Bright.md
bright.md2014Portland, United States$30.06M59
Provider of virtual telehealth and physician assistant for hospitals and patients
eConsult
econsult.net2011London, United Kingdom$16M58
Form-based consultation software is provided for patients and healthcare providers.
MediQuo
mediquo.com2017Barcelona, Spain$12.85M–
Health professionals are connected to patients through a telemedicine platform.
RxLive
rxlive.com2017St. Petersburg, United States$8.64M–
Telehealth platform connects patients with pharmacists via video consultations.
Summus Global
summusglobal.com2015New York, United States$71.34M–
Online platform providing telehealth solution for doctors and patients
Premium access

Detailed competitors of Gloheal

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Digital Health & Telemedicine

10 companies that operate in the same segment as Gloheal (Digital Health & Telemedicine), ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Tata 1mg
Provider of an online pharmacy with doctor listing and teleconsultation services
2015Delhi, Delhi, IndiaUSD 230.8 MUSD 328.97 M5,212
MediBuddy
Online platform offering multiple healthcare services
2013Bengaluru, Karnataka, IndiaUSD 199.22 MUSD 62.4 M52
GoodRx
An application is provided for comparing prescription drug prices nationwide.
2011Santa Monica, California, United StatesUSD 22.21 MUSD 796.85 M1,063
Zocdoc
Healthcare appointments are booked online via Zocdoc's platform.
2007New York, New York, United StatesUSD 425.97 MUSD 4.66 M1,365
SastaSundar
An online marketplace for healthcare products is operated.
2011Kolkata, West Bengal, IndiaUSD 38.26 M––
Alto Pharmacy
Alto Pharmacy is focused on providing convenient prescription delivery services.
2015San Francisco, California, United StatesUSD 591.64 M–802
One Medical
Membership-based primary care platform is offered for employees and consumers.
2007San Francisco, California, United StatesUSD 402.56 M––
Amwell
Telehealth solutions are provided for doctors and patients' consultations.
2006Boston, Massachusetts, United StatesUSD 887.35 MUSD 115.54 M742
Ro
Digital health services for men's wellness are offered by Ro.
2017New York, New York, United StatesUSD 1.03 B–1,485
23andMe
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits
2006Sunnyvale, California, United StatesUSD 943.53 MUSD 189.9 M562
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Gloheal

Tata Communications: CLSA on Tata Communications Maintains Outperform, Target Price ₹2,600; Q2FY27 revenue rose 10% YoY to ₹66.9bn, while EBITDA increased 21% to ₹14.2bn, beating estimates by 10% as margins expanded to 21.3%; data and digital services drove growth, PAT jumped 86%, and CLSA retains its forecast of 15% consolidated EBITDA CAGR through FY29.
Exchange Update • 5 days ago
Tata Communications: Aims For Profitable Growth And EBITDA Expansion With Confidence For The Current Year, Spotting Chances In Network, Cloud, Infrastructure, And Interaction Fabric.
Exchange Update • 5 days ago
Tata Communications: Aims To Achieve EBITDA Positivity Soon By Focusing On Revenue Growth, Better Revenue Mix, And Operating Efficiency. Core Connectivity Margins For The Quarter Are Estimated At About 44.8% And Expected To Remain Stable.
Exchange Update • 5 days ago
TATACOMM: Q2 CONS NET PROFIT 3.4B RUPEES VS 1.83B (YOY); EST 3.3B
Exchange Update • 6 days ago
TATACOMM: Q2 REVENUE 67B RUPEES VS 60.99B (YOY)
Exchange Update • 6 days ago
TATACOMM: Q2 EBITDA 14.21B RUPEES VS 11.73B (YOY); Q2 EBITDA MARGIN 21.26% VS 19.4% (YOY)
Exchange Update • 6 days ago
Tata Communications: Board Agrees to Move Full Stake in Kaleyra Inc. to Subsidiary TCNL to Streamline Company Structure, Maintaining Overall Ownership and Interest.
Exchange Update • 6 days ago
Tata Communications: Air India Enhances Global Travel With EasyRoam Travel Sim Powered By Co
Exchange Update • 13 days ago
Tata Communications: Issues Commercial Paper Worth 5.5 Billion Rupees
Exchange Update • 22 days ago
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26% in 1 year, according to analysts - The Economic Times
Economic Times • 23 days ago
Premium access

Complete news archive for Gloheal

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gloheal

Gloheal was founded in 2015.

Gloheal is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Gloheal has 5,895 employees.

The primary company behind Gloheal, Tata Communications Limited, reported revenue of ₹25,104 Cr for FY 2026, up 8% year on year.

Gloheal provides a virtual consultation platform for users, focusing on healthcare and services, providing telehealth services, consultation platforms, and virtual services. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.

Gloheal's top competitors include Amwell, eVisit and Truepill.

Yes, Gloheal is publicly traded on NSE under the ticker symbol TATACOMM.

Gloheal operates through Tata Communications Limited.

The legal entities of Gloheal currently have 10 directors, including Krishnakumar Natarajan, Ashok Sinha, Ganapathy Subramaniam Natarajan and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available